Sentences with phrase «hiv vaccine research»

Did you know that Microsoft is involved in HIV vaccine research?

The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.

That money had helped fund the HIV vaccine research.

As for HIV vaccine research, this issue features a perspective piece authored by one of IAVI's own scientists, Devin Sok.

Yet the pace of HIV vaccine research is now growing so swiftly that the scientific goal of conducting and completing a clinical trial may be threatened by a higher ethical obligation — to inform those taking part in the study that the original scientific basis for the research may have been modified by later work.

Since its inception in 1986, MHRP has emerged as a world leader in HIV vaccine research, threat assessment and epidemiology, HIV diagnostics and remission research.

They also celebrated the future of HIV vaccine research in South Africa.

We are in the midst of an unprecedented time in HIV vaccine research; we have four concurrent efficacy trials underway, which will collectively enroll 12,200 volunteers in the search for an HIV vaccine over the next few years.

Given these early disappointments, what can we expect from HIV vaccine research in the future?

This HIV vaccine research study is being conducted in collaboration with Muhimbili University (MUHAS)

«We are in the midst of an unprecedented time in HIV vaccine research,» said Dr. Larry Corey, who leads the HIV Vaccine Trials Network.

The trials would be for proof of concept, to show whether researchers can, for the first time in humans, stimulate the right B cells to start the process of making broadly neutralizing antibodies, long considered the «holy grail» of HIV vaccine research because they defend against infection by a broad spectrum of HIV strains.

This next stage in HIV vaccine research requires a strengthened global strategy that

VIDD Director Dr. Julie McElrath has called the approach «the next wave» of HIV vaccine research.

There have been other key advances in HIV vaccine research over the past five years.

The HVTN 100 study is part of a larger HIV vaccine research endeavor led by a group called the Pox - Protein Public - Private Partnership, or the P5 — a diverse set of public and private organizations, including MHRP, committed to building on the success of RV144.

NIH scientists have discovered a mechanism involved in stabilizing key HIV proteins and thereby concealing sites where some of the most powerful HIV neutralizing antibodies bind, findings with potential implications for HIV vaccine research.

Global spending for HIV vaccine research increased from $ 186 million in 1997 to $ 759 million in 2005, according to the Joint United Nations Program on HIV / AIDS.

Future HIV vaccine research should consider the balance between responses that favor protection and those that lead to susceptibility to infection.

Not exact matches

Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network; Past President and Director, Fred Hutchinson Cancer Research Center Dr. Diane Havlir, Professor of Medicine, University of California, San Francisco Moderator: Siobhan O'Connor, Time Magazine

«HIV - 1 viruses transmitted at birth are resistant to antibodies in mother's blood: New research supports creation of vaccine to boost mother's immune response to HIV - 1 before delivery.»

Developing a vaccine against HIV is still our best hope for containing the AIDS pandemic, says Danilo Casimiro, Merck's director of basic vaccine research.

In the US, for example, the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, is a hub for HIV research, and its Vaccine Research Center continues to focus on HIV in preference to other dresearch, and its Vaccine Research Center continues to focus on HIV in preference to other dResearch Center continues to focus on HIV in preference to other diseases.

Ebola is one of a number of viruses, including HIV and dengue, that have not surrendered to vaccines after decades of intensive research.

«The best explanation for what we are seeing is that frequently, after exposure to HIV, a few cells in the genital tract are infected, without establishment of a systemic infection,» says senior investigator Eric Hunter, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine, Emory Vaccine Center, and Yerkes National Primate Research Center.

In August, the agency announced a new list of priorities that puts vaccines and therapies high on the list and research not directly related to HIV infection further down.

Hope for a vaccine One possible implication of this line of research is the development of an HIV vaccine.

Now a research team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they deresearch team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they deResearch Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV - infected individual and determined sequential structures that point to how they developed.

Contributing to work on smallpox, polio, and vaccine development, primates allow research on potential treatments for hepatitis C and B, Ebola and Marburg viruses, and HIV / AIDS.

This could lead to new HIV vaccine strategies that are able to stimulate the rare precursors of these protective antibodies,» says Professor Lynn Morris, from the National Health Laboratory Service in the Wits School of Pathology who leads the research team at the NICD.

The team was led by Barton Haynes, M.D., director of the Duke Center for HIV / AIDS Vaccine Immunology - Immunogen Discovery (CHAVI - ID) and the Duke Human Vaccine Institute, and John Mascola, M.D., director of the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Thirty years of struggle and research have led to dozens of treatments for HIV / AIDS — although both a cure and an effective vaccine remain elusive

«We are pleased to have demonstrated such a potent and durable immune response to the vaccine,» said the study's lead author, Sita Awasthi, PhD, a research associate professor of Infectious Diseases at Penn. «If found effective in clinical trials, the vaccine will have a huge impact on reducing the overall prevalence of genital herpes infections and could reduce new HIV infections as well, especially in high - burden regions of sub-Saharan Africa.»

Despite years of trying, scientists still haven't created an HIV vaccine that can protect people against the virus, says Alan Aderem, a biologist at the Center for Infectious Disease Research in Seattle.

«We've shown that a specific type of these cells, known as follicular helper T (Tfh) cells are not only necessary, but are a limiting factor that differentiates between an average and a potent antibody response to HIV,» says Crotty, a scientific collaborator with the Center for HIV / AIDS Vaccine Immunology & Immunogen Discovery (CHAVI - ID), a major research consortium led by The Scripps Research Inresearch consortium led by The Scripps Research InResearch Institute.

The next step in this research is to analyze the glycan composition and glycan - free sites on the natural, or «native,» form of HIV, not just an HIV - like vaccine candidate.

Now scientists at The Scripps Research Institute (TSRI) have developed a method to analyze the glycan shield on HIV's protective outer glycoprotein, developed as a potential HIV vaccine candidate.

The move has outraged the broader community because the U.S. Military HIV Research Program plays a unique role in AIDS vaccine development.

The results came as a surprise to HIV - vaccine skeptics in the AIDS (acquired immunodeficiency syndrome) research field, whose numbers have increased after years of failed vaccine trials.

Dr. Michael's research interests include HIV molecular pathogenesis and host genetics, HIV clinical research, and HIV vaccine development.

This approach could be especially useful for delivering HIV vaccines and for stimulating the body's immune system to attack tumors, says Irvine, who is also a member of MIT's Koch Institute for Integrative Cancer Research.

Recent research has yielded new information about immune responses associated with — and potentially responsible for — protection from HIV infection, providing leads for new strategies to develop an HIV vaccine.

The research, published in the September issue of Immunity, is part of a broad reverse - engineering effort by scientists around the world to use antibodies isolated from HIV - infected people to guide the development of a successful vaccine.

Scientists at The Scripps Research Institute (TSRI) have made a discovery that could speed efforts to develop a successful HIV vaccine.

In a previously published paper, Barouch and colleagues, including Colonel Nelson L. Michael, MD, PhD, director of the Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) and Stephen Thomas, MD, Upstate Medical University, State University of New York, demonstrated that three different vaccine candidates provided robust protection against Zika virus in both mice and rhesus monkeys.

[Raymond S. Weinstein et al., http://bit.ly/co5llO] Further research confirming the relationship between stopping the smallpox vaccine and the rise of HIV would not surprise William McNeill.

«The discovery of this new antibiotic was an unexpected result of basic research on HIV proteins,» said senior author Ronald Montelaro, Ph.D., professor and co-director of Pitt's Center for Vaccine Researcresearch on HIV proteins,» said senior author Ronald Montelaro, Ph.D., professor and co-director of Pitt's Center for Vaccine ResearchResearch (CVR).

«This basically changes our whole view of the pathogenesis of HIV infection,» says Daniel Douek, chief of the Human Immunology Section at the National Institutes of Health's Vaccine Research Center.

The dilemma for vaccine research is that these cells are also the target cells for an infection with HIV or SIV.

«We have learned in that period of time how formidable an adversary HIV is,» says immunologist Wayne Koff, senior vice president for research and development at the International AIDS Vaccine Initiative (IAVI).